Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    Article Recommendations from Our Deputy and Senior Editors
    Cancer Immunol Res September 2 2016 4 (9) 717-717; DOI:10.1158/2326-6066.CIR-16-0WWR

Book Review

  • Book Review
    From Bratislava to New York: A Scientist's Tale
    Sir Marc Feldmann
    Cancer Immunol Res September 2 2016 4 (9) 718-718; DOI:10.1158/2326-6066.CIR-16-0172

    A review of Love and Science: A Memoir by Jan Vilcek, Seven Stories Press, 2016

In the Spotlight

  • In the Spotlight
    Zeroing in on Tumor-Reactive TILs
    Pamela S. Ohashi
    Cancer Immunol Res September 2 2016 4 (9) 719-719; DOI:10.1158/2326-6066.CIR-16-0179

Masters of Immunology

  • Masters of Immunology
    About the Master
    Cancer Immunol Res September 2 2016 4 (9) 720-720; DOI:10.1158/2326-6066.CIR-16-0196

  • Masters of Immunology
    Regulatory T Cells: Differentiation and Function
    George Plitas and Alexander Y. Rudensky
    Cancer Immunol Res September 2 2016 4 (9) 721-725; DOI:10.1158/2326-6066.CIR-16-0193

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures | AuthorChoice
    The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
    Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian
    Cancer Immunol Res September 2 2016 4 (9) 726-733; DOI:10.1158/2326-6066.CIR-16-0072

    Tumor cell–intrinsic metabolic factors, a hallmark of kidney cancer, may contribute to anti–PD-1 treatment resistance. This intersection between cancer immunology and metabolism supports an emerging theme of discovery for tumor type–specific biomarkers for immune checkpoint blocking therapies.

Research Articles

  • Research Articles
    Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor
    Anna Pasetto, Alena Gros, Paul F. Robbins, Drew C. Deniger, Todd D. Prickett, Rodrigo Matus-Nicodemos, Daniel C. Douek, Bryan Howie, Harlan Robins, Maria R. Parkhurst, Jared Gartner, Katarzyna Trebska-McGowan, Jessica S. Crystal and Steven A. Rosenberg
    Cancer Immunol Res September 2 2016 4 (9) 734-743; DOI:10.1158/2326-6066.CIR-16-0001

    Effective adoptive T-cell therapy requires multiple tumor-epitope reactive T-cell clones. Fresh TILs were found to frequently contain such cells. Their TCRs were rapidly isolated based only on their frequency and could be used for personalized TCR-gene therapy.

  • Research Articles
    Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma
    Sebastian Theurich, Sacha I. Rothschild, Michael Hoffmann, Mario Fabri, Andrea Sommer, Maria Garcia-Marquez, Martin Thelen, Catherine Schill, Ramona Merki, Thomas Schmid, Dieter Koeberle, Alfred Zippelius, Christian Baues, Cornelia Mauch, Christian Tigges, Alexander Kreuter, Jan Borggrefe, Michael von Bergwelt-Baildon and Max Schlaak
    Cancer Immunol Res September 2 2016 4 (9) 744-754; DOI:10.1158/2326-6066.CIR-15-0156

    Too few patients benefit from immune checkpoint inhibition alone. However, patients with melanoma receiving systemic anti-CTLA-4 plus localized treatments had significantly prolonged overall survival. In a multivariate analysis, adding local treatment was an independent factor for improved survival.

  • Research Articles
    Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
    Benedetto Farsaci, Renee N. Donahue, Italia Grenga, Lauren M. Lepone, Peter S. Kim, Brendan Dempsey, Janet C. Siebert, Nuhad K. Ibrahim, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom
    Cancer Immunol Res September 2 2016 4 (9) 755-765; DOI:10.1158/2326-6066.CIR-16-0037

    Refined subsets of peripheral blood immune cells were assessed prior to therapy in two clinical trials. The resultant “peripheral immunoscores,” compiled through methodology potentially generalizable to other trials, were correlated with clinical benefit in patients receiving vaccine therapy.

  • Research Articles | AuthorChoice
    Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
    George Fromm, Suresh de Silva, Louise Giffin, Xin Xu, Jason Rose and Taylor H. Schreiber
    Cancer Immunol Res September 2 2016 4 (9) 766-778; DOI:10.1158/2326-6066.CIR-15-0228

    Local anticancer therapies can increase antitumor efficacy while reducing toxicities. Cellular vaccines that locally secreted costimulation ligands produced stronger, more specific T-cell activation and tumor rejection with lower ligand concentrations than did vaccines combined with systemic antibody agonists.

  • Research Articles
    Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
    Mariko Ishibashi, Hideto Tamura, Mika Sunakawa, Asaka Kondo-Onodera, Namiko Okuyama, Yasuko Hamada, Keiichi Moriya, Inhak Choi, Koji Tamada and Koiti Inokuchi
    Cancer Immunol Res September 2 2016 4 (9) 779-788; DOI:10.1158/2326-6066.CIR-15-0296

    B7-H1 suppresses T cells by binding to PD-1, but it is unclear how binding to B7-H1 on cancer cells affects tumors. “Reverse signaling” of B7-H1 on myeloma cells was found to induce drug resistance through the Akt-signaling pathway.

  • Research Articles
    Mutation Drivers of Immunological Responses to Cancer
    Eduard Porta-Pardo and Adam Godzik
    Cancer Immunol Res September 2 2016 4 (9) 789-798; DOI:10.1158/2326-6066.CIR-15-0233

    Tumor mutations create neoantigens that increase their immunogenicity but also enable new avenues of immune escape. DomainXplorer analyzes distributions of mutations in cancer genomes searching for correlations with immune response that are not seen by gene level methods.

  • Research Articles
    Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
    Andrew L. Doedens, Mark P. Rubinstein, Emilie T. Gross, J. Adam Best, David H. Craig, Megan K. Baker, David J. Cole, Jack D. Bui and Ananda W. Goldrath
    Cancer Immunol Res September 2 2016 4 (9) 799-811; DOI:10.1158/2326-6066.CIR-15-0178

    Tumor-infiltrating CD8+ T cells were profoundly resistant to IL15 complexes, so could not induce tumor regression. Their gene-expression signature was compared with that of productive cytotoxic responses and known differentiation states to determine how to restore antitumor function and cytokine responsiveness.

Back to top
PreviousNext
Cancer Immunology Research: 4 (9)
September 2016
Volume 4, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • What We're Reading
  • Book Review
  • In the Spotlight
  • Masters of Immunology
  • Cancer Immunology Miniatures
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement